National Peroxide FY26 turnaround, ₹7 dividend, CFO change

Stock snapshot and what triggered fresh attention

National Peroxide Limited (BSE: 544205) stayed in focus on April 30, 2026 after the company released audited results, recommended a final dividend, and disclosed a change in finance leadership. The stock was quoted at ₹456.35, up ₹19.00 (4.34%) on BSE as of 3:29 PM IST on April 30, 2026. The updates were routed through filings under SEBI’s Listing Obligations and Disclosure Requirements (LODR), including announcements tagged to Regulation 30. For investors tracking smaller chemical names, the combination of a profitability reversal and a dividend proposal made the day’s disclosures particularly relevant. The filings also gave clarity on management continuity in a function that has seen multiple changes in the past year.

Board meeting on April 30: audited results and dividend proposal

The company’s corporate action calendar listed April 30, 2026 for “Audited Results & Final Dividend,” and the board’s disclosures followed the same date stamp. National Peroxide said its board recommended a final dividend of ₹7 per equity share for FY26. The company described it as a 70% dividend, and clarified that it remains subject to shareholder approval at the upcoming AGM. Alongside the dividend recommendation, the company issued “Financial Results for Quarter and Year Ended March 31, 2026” on the same day. These actions indicate that the board completed its annual results process and paired it with a shareholder payout proposal.

FY2026 turnaround: income and profit move back into the black

National Peroxide reported a sharp improvement in FY2026 performance compared with FY2025. Total income for FY2026 was ₹295.68 crore, and net profit after tax (PAT) was ₹11.04 crore. In the previous year, the company had reported a loss of ₹2.25 crore. Earnings per share (basic and diluted) for FY2026 was reported at ₹19.20, compared with a loss per share of ₹3.91 in FY2025. The FY2026 set of numbers positioned the year as a clear reversal from the loss-making FY2025 base.

Q3 FY26 results: quarterly profit after a prior-year loss

For Q3 FY26, the company reported revenue from operations of ₹69.09 crore, up from ₹62.16 crore in Q3 FY25. Total income for the quarter stood at ₹69.99 crore, versus ₹62.52 crore in the corresponding quarter of the prior year. The swing was most visible in bottom line performance, with Q3 FY26 PAT of ₹1.83 crore versus a loss of ₹1.52 crore in Q3 FY25. Basic EPS for Q3 FY26 was ₹3.19, compared with ₹(2.64) in Q3 FY25. These figures were approved by the board at its meeting held on February 5, 2026.

Nine-month FY26 view: profit reported, but below prior year

For the nine months ended December 31, 2025, National Peroxide reported revenue from operations of ₹204.03 crore, compared with ₹213.17 crore for the corresponding period of the previous year. Total income for the nine-month period was ₹208.62 crore, versus ₹217.65 crore a year earlier. The company reported net profit of ₹3.11 crore for 9M FY26, compared with ₹4.24 crore in 9M FY25. While the company remained profitable over the nine months, the disclosed numbers show a year-on-year reduction in profit for that period, even as Q3 itself marked a turnaround from loss to profit.

Exceptional item flagged in Q3 and what it relates to

The company disclosed an exceptional item of ₹0.58 crore during Q3 FY26. It attributed this to actuarial valuation of past service costs for employee benefits under the newly implemented Social Security Code. Total comprehensive income for the quarter was reported at ₹2.51 crore, compared with a loss of ₹1.59 crore in the previous year’s quarter. The disclosure helps separate one-off employee-benefit related costs from the underlying quarter’s operating performance.

Management changes: CFO-CRO transition set for June 2026

In a filing titled “Resignation of Chief Financial Officer (CFO),” National Peroxide announced a planned leadership change in its finance department. Interim CFO and CRO Mr. Amit Goriwale will step down effective May 31, 2026. The company said Mr. Chirag Kothari has been appointed as the new CFO and CRO effective June 1, 2026. The filing indicated that the transition appears planned, with Mr. Goriwale expected to remain with the company in another role. Earlier, the company had disclosed that Mr. Goriwale was appointed Interim CFO and Interim CRO effective December 18, 2025.

Governance additions: company secretary appointment from March 2026

Separate from the CFO update, the board also approved the appointment of Mr. Akshay Satasiya as Company Secretary and Compliance Officer, and as a Key Managerial Personnel, with effect from March 9, 2026. The company described him as an Associate Member of the Institute of Company Secretaries of India, with over 10 years of experience in secretarial, compliance, and corporate governance functions. For listed companies, such appointments are closely tracked because they influence disclosure quality, compliance execution, and board processes.

Corporate actions and key dates investors are tracking

The company’s corporate actions list showed multiple results-related board actions over the past year, including quarterly results dates and audited results. It also listed April 30, 2026 for audited results and final dividend. These dates provide context for how frequently the company has been approaching the market with updates and when shareholders can expect decisions to be formalised through AGM approval.

Market and credit context: what else was flagged in disclosures

A separate update cited India Ratings downgrading the company’s bank loan facilities from ‘IND A’ to ‘IND A-’ with a Negative Outlook. The same note stated revenue declined 14% YoY to ₹286.90 crore in FY25, while EBITDA fell 50% to ₹15.20 crore. In addition, one dashboard-style disclosure listed the company’s operating margin for the current financial year at 5.30183983212143%. It also stated the current-year dividend as ₹0 with a 0% yield, which sits alongside the later board recommendation of a ₹7 final dividend that is pending shareholder approval.

Conclusion: three takeaways from the April 30 filings

National Peroxide’s April 30 disclosures combined three investor-relevant signals: audited FY2026 results showing a return to profit, a recommended final dividend of ₹7 per share subject to AGM approval, and a CFO-CRO handover effective June 1, 2026. The Q3 FY26 numbers highlighted a quarter-level turnaround from loss to profit, while the nine-month comparison showed profitability but lower year-on-year profit. Over the next cycle, shareholders are likely to track the AGM outcome on the dividend, and the execution of the finance leadership transition on the stated effective dates.